Recombinant N-Terminal Slit2 Inhibits TGF-β-Induced Fibroblast Activation and Renal Fibrosis

Area of Science:

• Nephrology
• Molecular Biology
• Immunology

Background:

• Chronic kidney disease (CKD) involves intertwined fibrosis and inflammation pathways with limited therapies.
• Slit glycoproteins, signaling via Roundabout (Robo) receptors, exhibit anti-inflammatory effects by regulating leukocyte cytoskeletal organization.
• Fibroblast responses to TGF-β also necessitate cytoskeletal reorganization.

Purpose of the Study:

• To investigate if Slit2 influences TGF-β-induced renal fibrosis.
• To determine the therapeutic potential of Slit2 in mitigating kidney injury.

Main Methods:

• Utilized cultured renal fibroblasts expressing Slit2 and Robo-1.
• Administered N-terminal and C-terminal fragments of Slit2 in mouse models of postischemic renal fibrosis and obstructive uropathy.

Main Results:

• The bioactive N-terminal Slit2 fragment inhibited TGF-β-induced collagen synthesis, actin cytoskeletal reorganization, and Smad2/3 activity in cultured fibroblasts.
• In vivo, N-terminal Slit2 treatment attenuated renal fibrosis and preserved function in mouse models.
• The inactive C-terminal Slit2 fragment showed no significant effects in either in vitro or in vivo experiments.

Conclusions:

• Slit2, specifically its N-terminal fragment, directly inhibits renal fibroblast activation and TGF-β-induced fibrosis.
• Recombinant Slit2 administration presents a novel therapeutic strategy to combat chronic kidney injury by reducing both inflammation and fibrosis.
• This approach holds promise for treating conditions like ischemic and obstructive renal insults.